Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer.
It promotes better understanding of cancer and highlights risk factors and ways in which we can all reduce our chances of certain cancers. It advocates for continued clinical research into cancers and effective therapies and treatments.
Source: The Global Cancer Observatory
Cromos Pharma’s commitment to cancer clinical researchAt Cromos Pharma we are proud to play our part by supporting our clients in developing novel and innovative treatments for a wide range of cancers.
Since 2004, we have been providing offering fully integrated clinical research services delivering all aspects of clinical trials in all clinical phases. Our very first research project was in oncology and since then we have been supporting our clients in cancer clinical research. We have successfully managed hundreds of studies ranging from innovative treatments to cost-advantaged generic and biosimilar therapies, from targeted therapies to companion treatments to help cancer patients withstand the rigors of chemotherapy and radiation.
We remain committed to this work and to accelerating the development of cancer treatments to reduce mortality and help improve the lives of all of those living with cancer worldwide.
Read more about World Cancer Day here www.worldcancerday.org
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.